Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 13%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is currently trading at a low P/S ratio in comparison to its industry peers and has shown strong revenue growth in recent years. Alkermes' stock has potential for growth, with a focus on developing treatments for psychiatric diseases and promising pipeline assets. Upcoming data for drugs targeting sleep disorders and ADHD could further drive the stock's success. The company's low P/S ratio and strong revenue growth make it an attractive investment opportunity with potential for competition and M&A activity.

Bears say

Alkermes is facing challenges in differentiating their drug efficacy, with low diagnosis rates and few approved treatments, placing them at a disadvantage to competitors. Despite their recent acquisition and position in the market, their long-term growth outlook and potential for disruptions in the standard-of-care appears low, leading to a negative outlook on their stock. Their financials, such as their discounted cash flow analysis and small ph1b study, do not inspire confidence in the potential success of their products.

Alkermes (ALKS) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 13% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 15 analysts, Alkermes (ALKS) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.